Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer
Yuna Kim(Yonsei University), Ki Cheong Park(Gangneung–Wonju National University)
Cited by 10
Related Papers
A new histone deacetylase inhibitor improves liver fibrosis in <scp>BDL</scp> rats through suppression of hepatic stellate cells
|British Journal of Pharmacology|2014|58
Oncostatin M Inhibits Proliferation of Rat Oval Cells, OC15-5, Inducing Differentiation into Hepatocytes
|American Journal Of Pathology|2005|44
Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer
|Neoplasia|2017|20
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma
|International Journal of Molecular Sciences|2023|12
Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models
|International Journal of Molecular Sciences|2021|11